The complex analysis of efficiency and compliance of modern ferrum medication for treatment of anemia in pregnant women

Abstract

There were analysed the results of treatment efficiency and compliance of Ferrum medication in pregnant women with anemia using non-ionic compounds Fe (III) — Ferlatum (1st group) and ionic compounds Fe (II)— Sorbiferdurules (2nd group). Compounds of Fe (III) were more compliant in treatment of anemia making Ferlatum the medication of choise in treatment of anemia during pregnancy.

Keywords

anemia in pregnancy / treatment / protein succinilatic / Fe (III)

References

[1] Бурлее В.А., Павлович С.В. Железодефицит у беременных (обзор литературы).//Пробл. репрод. 2002; 4: 29-33.

[2] Казюкова Т.В., Самсыгина В.А., Калашникова Г.В. и др. Новые возможности ферротерапии железодефицитной анемии.//Клин. фармакол. и тер. 2000; 2: 88-91.

[3] Шехтман М.М. Железодефицитная анемия и беременность.//Гинекология 2000; 6:164-172.

[4] Джаманаева К.Б. Патогенетические механизмы развития анемии беременных.//Акуш. гин. перинат. 2000; 2: 24- 28.

[5] Cremonesi R., Caramazza I. Chemical and biological characterization of iron-protein succinylate (ITF 282).// Int. Journ. Of Clin.

[6] Pharmacol. Ther and Toxicol. 1993; 31(1): 40-51.

[7] Caramazza I., Anndriuoli G., Scagnol I., Del Soldato P. Comparison of anti-aneaemic effects of iron-protein succinylate (ITF 282) and Ferrous Sulphate in the rat.//Drugs Exprt Clin res., 1990, XVI (7): 333-42.

[8] Haram K. Iron supplementation in pregnancy - evidence and controversies. //Acta Obstet. Gynecol. Scand. 2001; 80: 683- 88.

[9] Kartikasari A.E., Georgiou N.A., Visseren F.L. et al. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells.//Arterioscler Tromb Vasc Biol. 2004; 24(12): 2257-62.

[10] Pagella P.G., Bellavite O., Agozzino S., Doni G.C. Pharmacological and toxicological studies on an iron succinyl-protein complex (ITF 282) for oral treatment of iron deficiency anemia.//Arzneim-Forsch/Drug Res. 1994; 43(H): 952-8.

[11] Forster R. Iron-protein succinylate: preclinical safety assessment.//Int. Journ. Of Clin. Pharmacol. Ther and Toxicol. 1993; 31(2): 53-60.

RIGHTS & PERMISSIONS

Eсо-Vector